指南与共识冠心病血脂与心血管预防

ACC/AHA与ESC双联抗血小板治疗指南对比

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.
指南 / 共识 · J Am Coll Cardiol · 2018-01-01

本文对比了ACC/AHA与ESC关于双联抗血小板治疗(DAPT)的最新指南更新,聚焦于P2Y12抑制剂选择及DAPT最佳疗程,以平衡缺血与出血风险。文章梳理了两大指南的共同领域、一致信息及推荐管理策略的差异。

要点

  • DAPT是预防冠心病患者动脉粥样硬化血栓并发症的基石。
  • 处方DAPT需选择合适P2Y12抑制剂并确定最佳疗程以最小化缺血与出血风险。
  • ACC/AHA与ESC近期分别发布了关于DAPT疗程的聚焦更新推荐。

核心结论

  • ACC/AHA与ESC的DAPT指南更新在共同领域有一致信息,但在推荐管理策略上存在差异。

研究设计与样本

  • 指南对比研究:对比ACC/AHA与ESC各自发布的DAPT聚焦更新推荐。

主要发现

  • 两大指南均关注P2Y12抑制剂选择和DAPT最佳疗程以平衡缺血与出血风险。
  • 文章 delineates 了两大指南的共同领域、一致信息和推荐管理策略差异。

临床怎么用

  • 临床处方DAPT时应参考ACC/AHA与ESC指南更新,根据患者临床特征和情况选择P2Y12抑制剂及确定疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y12 inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient's clinical characteristic and circumstance. Recently, a guideline writing committee from the American College of Cardiology/American Heart Association (ACC/AHA) and a task force from the European Society of Cardiology (ESC) released their respective focused update recommendations on "Duration of DAPT in Patients with CAD" (ACC/AHA) and "DAPT in CAD" (ESC). This paper aims to review the ACC/AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018. PMID: 30522654. doi:10.1016/j.jacc.2018.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。